Nuformix (LSE:NFX) Additional Paid-In Capital : £6.67 Mil(As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Additional Paid-In Capital?

Nuformix's quarterly additional paid-in capital increased from Sep. 2021 (£6.39 Mil) to Mar. 2022 (£6.50 Mil) and increased from Mar. 2022 (£6.50 Mil) to Sep. 2022 (£6.67 Mil).

Nuformix's annual additional paid-in capital increased from Mar. 2020 (£4.48 Mil) to Mar. 2021 (£6.39 Mil) and increased from Mar. 2021 (£6.39 Mil) to Mar. 2022 (£6.50 Mil).

Nuformix Additional Paid-In Capital Historical Data

The historical data trend for Nuformix's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Additional Paid-In Capital Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Additional Paid-In Capital

Get a 7-Day Free Trial

2.93

4.48

6.39

6.50

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Additional Paid-In Capital	Get a 7-Day Free Trial									6.39	6.39	6.50	6.67	6.64

Nuformix Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Nuformix Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Nuformix's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuformix (LSE:NFX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.